TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF THE ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET 26
1.4 CURRENCY AND PRICING 27
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.6 MULTIVARIATE MODELLING 37
2.7 TEST TYPE SEGMENT LIFELINE CURVE 37
2.8 MARKET END USER COVERAGE GRID 38
2.9 DBMR MARKET POSITION GRID 39
2.10 VENDOR SHARE ANALYSIS 40
2.11 SECONDARY SOURCES 41
2.12 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 44
4.1 PESTLE ANALYSIS 45
4.2 PORTER'S FIVE FORCES MODEL 46
5 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT 47
6 REGULATORY FRAMEWORK 49
6.1 REGULATORY SCENARIO IN JAPAN 49
6.2 REGULATORY SCENARIO IN CHINA 49
7 MARKET OVERVIEW 51
7.1 DRIVERS 53
7.1.1 RISING INCIDENCE OF BLADDER CANCER ASIA PACIFICLY 53
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER 53
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY 54
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS 54
7.2 RESTRAINTS 55
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER 55
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES 55
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS 55
7.3 OPPORTUNITIES 56
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER 56
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS 56
7.3.3 INCREASE IN THE GERIATRIC POPULATION 57
7.4 CHALLENGES 57
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING 57
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES 58
8 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 59
8.1 OVERVIEW 60
8.2 CYSTOSCOPY 63
8.3 URINE LAB TEST 63
8.3.1 URINE CYTOLOGY 65
8.3.2 URINALYSIS 65
8.3.3 URINE TUMOR MARKER TEST 65
8.3.4 URINE CULTURE 65
8.3.5 OTHERS 65
8.4 BIOPSY 65
8.5 IMAGING TEST 66
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 67
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN 67
8.5.3 ULTRASOUND 67
8.5.4 INTRAVENOUS PYELOGRAM (IVP) 68
8.6 OTHERS 68
9 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES 69
9.1 OVERVIEW 70
9.2 STAGE IV 73
9.3 STAGE III 73
9.4 STAGE II 74
9.5 STAGE I 75
10 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 77
10.1 OVERVIEW 78
10.2 TRANSITIONAL CELL BLADDER CANCER 81
10.3 SQUAMOUS CELL BLADDER CANCER 82
10.4 OTHER CANCER TYPES 83
11 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY END USER 84
11.1 OVERVIEW 85
11.2 HOSPITAL 88
11.3 DIAGNOSTIC IMAGING CENTERS 88
11.4 CANCER RESEARCH INSTITUTES 89
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES 90
11.6 ASSOCIATED LABS 91
12 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 92
12.1 OVERVIEW 93
12.2 DIRECT TENDER 96
12.3 RETAIL SALES 96
13 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, BY REGION 98
13.1 ASIA-PACIFIC 99
13.1.1 CHINA 106
13.1.2 INDIA 108
13.1.3 JAPAN 110
13.1.4 SOUTH KOREA 112
13.1.5 THAILAND 114
13.1.6 SINGAPORE 116
13.1.7 INDONESIA 118
13.1.8 MALAYSIA 120
13.1.9 PHILIPPINES 122
13.1.10 AUSTRALIA 124
13.1.11 REST OF ASIA-PACIFIC 126
14 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 127
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 127
15 SWOT ANALYSIS 128
16 ASIA PACIFIC BLADDER CANCER DIAGNOSTICS MARKET 129
16.1 F. HOFFMANN- LA ROCHE LTD 129
16.1.1 COMPANY SNAPSHOT 129
16.1.2 REVENUE ANALYSIS 129
16.1.3 COMPANY SHARE ANALYSIS 130
16.1.4 PRODUCT PORTFOLIO 130
16.1.5 RECENT DEVELOPMENTS 130
16.2 MERCK KGAA 131
16.2.1 COMPANY SNAPSHOT 131
16.2.2 REVENUE ANALYSIS 131
16.2.3 COMPANY SHARE ANALYSIS 132
16.2.4 PRODUCT PORTFOLIO 132
16.2.5 RECENT DEVELOPMENT 132
16.3 THERMO FISHER SCIENTIFIC INC. 133
16.3.1 COMPANY SNAPSHOT 133
16.3.2 REVENUE ANALYSIS 133
16.3.3 COMPANY SHARE ANALYSIS 134
16.3.4 PRODUCT PORTFOLIO 134
16.3.5 RECENT DEVELOPMENT 134
16.4 KONINLIJKE PHILIPS N.V. 135
16.4.1 COMPANY SNAPSHOT 135
16.4.2 REVENUE ANALYSIS 135
16.4.3 COMPANY SHARE ANALYSIS 136
16.4.4 PRODUCT PORTFOLIO 136
16.4.5 RECENT DEVELOPMENT 136
16.5 BIO-RAD LABORATORIES, INC. 137
16.5.1 COMPANY SNAPSHOT 137
16.5.2 COMPANY SNAPSHOT 137
16.5.3 COMPANY SHARE ANALYSIS 138
16.5.4 PRODUCT PORTFOLIO 138
16.5.5 RECENT DEVELOPMENT 138
16.6 ABBOTT 139
16.6.1 COMPANY SNAPSHOT 139
16.6.2 REVENUE ANALYSIS 139
16.6.3 PRODUCT PORTFOLIO 140
16.6.4 RECENT DEVELOPMENT 140
16.7 AGILENT TECHNOLOGIES, INC. 141
16.7.1 COMPANY SNAPSHOT 141
16.7.2 REVENUE ANALYSIS 141
16.7.3 PRODUCT PORTFOLIO 142
16.7.4 RECENT DEVELOPMENT 142
16.8 AMBU A/S 143
16.8.1 COMPANY SNAPSHOT 143
16.8.2 REVENUE ANALYSIS 143
16.8.3 PRODUCT PORTFOLIO 144
16.8.4 RECENT DEVELOPMENT 144
16.9 BD 145
16.9.1 COMPANY SNAPSHOT 145
16.9.2 REVENUE ANALYSIS 145
16.9.3 PRODUCT PORTFOLIO 146
16.9.4 RECENT DEVELOPMENT 146
16.10 CANON MEDICAL SYSTEMS CORPORATION 147
16.10.1 COMPANY SNAPSHOT 147
16.10.2 REVENUE ANALYSIS 147
16.10.3 PRODUCT PORTFOLIO 148
16.10.4 RECENT DEVELOPMENT 148
16.11 CEPHEID 149
16.11.1 COMPANY SNAPSHOT 149
16.11.2 REVENUE ANALYSIS 149
16.11.3 PRODUCT PORTFOLIO 150
16.11.4 RECENT DEVELOPMENTS 150
16.12 FUJIFILM CORPORATION 151
16.12.1 COMPANY SNAPSHOT 151
16.12.2 REVENUE ANALYSIS 151
16.12.3 PRODUCT PORTFOLIO 152
16.12.4 RECENT DEVELOPMENTS 152
16.13 GENERAL ELECTRIC COMPANY 153
16.13.1 COMPANY SNAPSHOT 153
16.13.2 REVENUE ANALYSIS 153
16.13.3 PRODUCT PORTFOLIO 154
16.13.4 RECENT DEVELOPMENTS 154
16.14 HOLOGIC INC. 155
16.14.1 COMPANY SNAPSHOT 155
16.14.2 REVENUE ANALYSIS 155
16.14.3 PRODUCT PORTFOLIO 156
16.14.4 RECENT DEVELOPMENT 156
16.15 ILLUMINA INC 157
16.15.1 COMPANY SNAPSHOT 157
16.15.2 REVENUE ANALYSIS 157
16.15.3 PRODUCT PORTFOLIO 158
16.15.4 RECENT DEVELOPMENTS 158
16.16 MINFOUND MEDICAL SYSTEMS CO., 159
16.16.1 COMPANY SNAPSHOT 159
16.16.2 PRODUCT PORTFOLIO 159
16.16.3 RECENT DEVELOPMENTS 159
16.17 NEUSOFT CORPORATION 160
16.17.1 COMPANY SNAPSHOT 160
16.17.2 COMPANY SNAPSHOT 160
16.17.3 PRODUCT PORTFOLIO 161
16.17.4 RECENT DEVELOPMENT 161
16.18 QIAGEN 162
16.18.1 COMPANY SNAPSHOT 162
16.18.2 REVENUE ANALYSIS 162
16.18.3 PRODUCT PORTFOLIO 163
16.18.4 RECENT DEVELOPMENT 163
16.19 SIEMENS HEALTHCARE GMBH 164
16.19.1 COMPANY SNAPSHOT 164
16.19.2 REVENUE ANALYSIS 164
16.19.3 PRODUCT PORTFOLIO 165
16.19.4 RECENT DEVELOPMENT 166
16.20 TIME MEDICAL HOLDING. 167
16.20.1 COMPANY SNAPSHOT 167
16.20.2 PRODUCT PORTFOLIO 167
16.20.3 RECENT DEVELOPMENTS 167
17 QUESTIONNAIRE 168
18 RELATED REPORTS 171

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.